To commemorate WorldCancerDay2023 we spoke to a multidisciplinary team of researchers from the Institute of Cancer Therapeutics UniofBradford about their work in cancerresearch
Interview conducted by Danielle Ellis, B.Sc.Feb 3 2023 Thought LeadersThe Institute of Cancer TherapeuticsThe University of Bradford
My name is Hannah, and I joined the ICT 3 years ago. My cancer research career started with an undergraduate dissertation project. After my undergraduate project, I was keen to develop my research skills, so I started looking for Ph.D. positions. Luckily, a particularly interesting project was being advertised at Hull York Medical School under the supervision of Dr. Stephen Maher and Prof Michael Lind.
How have you seen the field of cancer therapeutics change throughout your career? It has changed significantly from reliance on cytotoxic ‘DNA-bashing’ compounds to the sophisticated targeted therapeutics we have today. - Dr Steve Shnyder What has been the most significant breakthrough in cancer therapeutics in recent years? The realization that harnessing the involvement of the tumor microenvironment is key to controlling tumor growth. - Dr Steve Shnyder
The theme for World Cancer Day 2023 is #CloseTheCareGap, which started in 2022 and will end in 2024. This year is all about uniting our voices and taking action. How do you believe both the research community and the general public can support cancer research and patients? As researchers, we need to listen to cancer patients more about their needs so that we can adjust plans for novel treatments accordingly in line with this.
Ireland Latest News, Ireland Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
World Cancer Day: 'GPs should take young people seriously'For World Cancer Day, we spoke to two young women who's cancers were misdiagnosed by GPs multiple times. The women say it took multiple appointments to finally be diagnosed and that GPs ruled out cancer almost immediately due to their age.
Read more »
30-year-old Bobi named world's oldest dog ever by Guinness World Records'From being condemned at birth to now being the oldest verified dog ever, Bobi's story is a miraculous one,' said Guinness World Records. He was born with three siblings to a family in Portugal, but they already had a lot of animals and had to put the puppies down, and Bobi escaped.
Read more »
Development and validation of an AI-enabled digital breast cancer assay to predict early-stage breast cancer recurrence within 6 years - Breast Cancer ResearchBackground Breast cancer (BC) grading plays a critical role in patient management despite the considerable inter- and intra-observer variability, highlighting the need for decision support tools to improve reproducibility and prognostic accuracy for use in clinical practice. The objective was to evaluate the ability of a digital artificial intelligence (AI) assay (PDxBr) to enrich BC grading and improve risk categorization for predicting recurrence. Methods In our population-based longitudinal clinical development and validation study, we enrolled 2075 patients from Mount Sinai Hospital with infiltrating ductal carcinoma of the breast. With 3:1 balanced training and validation cohorts, patients were retrospectively followed for a median of 6 years. The main outcome was to validate an automated BC phenotyping system combined with clinical features to produce a binomial risk score predicting BC recurrence at diagnosis. Results The PDxBr training model (n = 1559 patients) had a C-index of 0.78 (95% CI, 0.76–0.81) versus clinical 0.71 (95% CI, 0.67–0.74) and image feature models 0.72 (95% CI, 0.70–0.74). A risk score of 58 (scale 0–100) stratified patients as low or high risk, hazard ratio (HR) 5.5 (95% CI 4.19–7.2, p | 0.001), with a sensitivity 0.71, specificity 0.77, NPV 0.95, and PPV 0.32 for predicting BC recurrence within 6 years. In the validation cohort (n = 516), the C-index was 0.75 (95% CI, 0.72–0.79) versus clinical 0.71 (95% CI 0.66–0.75) versus image feature models 0.67 (95% CI, 0.63–071). The validation cohort had an HR of 4.4 (95% CI 2.7–7.1, p | 0.001), sensitivity of 0.60, specificity 0.77, NPV 0.94, and PPV 0.24 for predicting BC recurrence within 6 years. PDxBr also improved Oncotype Recurrence Score (RS) performance: RS 31 cutoff, C-index of 0.36 (95% CI 0.26–0.45), sensitivity 37%, specificity 48%, HR 0.48, p = 0.04 versus Oncotype RS plus AI-grade C-index 0.72 (95% CI 0.67–0.79), sensitivity 78%, specificity 49%, HR 4.6, p | 0.001 versus Oncotype
Read more »
Scientists create more efficient CAR immunotherapies using a molecular anchorAdding a molecular anchor to the key protein used to recognize cancer in cellular immunotherapies can make the treatments significantly more effective. Scientists at St. Jude Children's Research Hospital found that immune cells with the anchored protein increased cancer killing, regardless of their cell type or the kind of cancer targeted.
Read more »
Deletion of SNX9 alleviates CD8 T cell exhaustion for effective cellular cancer immunotherapy - Nature CommunicationsThe efficacy of T-cell-based cancer immunotherapies can be compromised by T cell exhaustion. Here the authors develop a human ex vivo exhaustion model and, based on a CRISPR-Cas9 screen, identify SNX9 as a regulator of T cell exhaustion, showing that SNX9 knockout is associated with improved T cell function and anti-tumor activity in preclinical cancer models.
Read more »
Cancer cases to top 500,000 a year by 2040 - a rise of a third, charity warnsCancer Research UK's analysis estimates that there will be 208,000 overall cancer deaths in the UK each year by 2040 - and that 76% of those deaths will be in people aged 70 and over.
Read more »